| ||||
Nuevo hallazgo publicado en la revista científica Cochrane genera serias dudas sobre la eficacia y seguridad de oseltamivir (Tamiflu®) EEUU, enero 2012. El documento fue comentado por Andrew Pollack en el New York Times, el cual poder resumirse en los siguientes párrafos: "Una nueva revisión de la evidencia médica, continúa planteando interrogantes sobre la seguridad y eficacia del medicamento antigripal, oseltamivir (Tamiflu®), en el cual Estados Unidos y otras naciones han gastado miles de millones de dólares en reservas para su uso por una posible pandemia de gripe". La revisión encontró "que el Tamiflu podría reducir la duración de los síntomas de la gripe por cerca de 21 horas, de los típicos seis o siete días. Sin embargo, "los investigadores dijeron que no podían confirmar otros dos efectos propuestos para el fármaco, a menudo citados como razones para su uso en una pandemia; esto son: reducción de las complicaciones de la gripe, como neumonía u hospitalizaciones, y reducción de la transmisión del virus. ".. Los revisores señalaron que su análisis se vio obstaculizado por el hecho de que el fabricante del medicamento, Roche, no había suministrado todos los datos de los ensayos clínicos que se había comprometido a proporcionar...." Acceda al documento en la siguiente dirección: http://www.thecochranelibrary. Saludos cordiales Equipo de GAPURMED y Excellencis | ||||
Mostrando las entradas con la etiqueta tamiflu. Mostrar todas las entradas
Mostrando las entradas con la etiqueta tamiflu. Mostrar todas las entradas
26 marzo, 2012
Oseltamivir
12 julio, 2009
Revisiones sobre Oseltamivir
Dos excelentes artículos que analizan la evidencia hasta ahora disponible acerca del oseltamivir (Tamiflu), ambos fueron escritos por destacados profesionales independientes quienes declaran no poseer ningún conflicto de interés.
El Oseltamivir en tiempos de gripe. Por el Dr. Pedro Politi, Profesor Adjunto de la Segunda Cátedra de Farmacología de la Universidad de Buenos Aires.
Abordaje terapéutico de la Gripe A H1N1: análisis del oseltamivir (Tamiflu). Por Martín Cañás, farmacólogo del Grupo Argentino para el Uso Racional del Medicamento (GAPURMED).
Gente........citen las fuentes originales!!!!!!!!!! El escrito de Martin fue publicado en la lista de atencionprimaria.
Fuente de esta entrada: http://farmacologiaymedicina.com/farmacologia-evidencia-tamiflu-oseltamivir/
Revisiones sobre Oseltamivir
Dos excelentes artículos que analizan la evidencia hasta ahora disponible acerca del oseltamivir (Tamiflu), ambos fueron escritos por destacados profesionales independientes quienes declaran no poseer ningún conflicto de interés.
El Oseltamivir en tiempos de gripe. Por el Dr. Pedro Politi, Profesor Adjunto de la Segunda Cátedra de Farmacología de la Universidad de Buenos Aires.
Abordaje terapéutico de la Gripe A H1N1: análisis del oseltamivir (Tamiflu). Por Martín Cañás, farmacólogo del Grupo Argentino para el Uso Racional del Medicamento (GAPURMED).
Gente........citen las fuentes originales!!!!!!!!!! El escrito de Martin fue publicado en la lista de atencionprimaria.
Fuente de esta entrada: http://farmacologiaymedicina.com/farmacologia-evidencia-tamiflu-oseltamivir/
08 julio, 2009
Efectos adversos del Tamiflu
Roche Laboratories has alerted healthcare professionals about neuropsychiatric events that have occurred in influenza patients taking Tamiflu (oseltamivir phosphate). Tamiflu is used to treat or prevent the flu in patients 1 year and older.
The company's letter says that there have been reports of self-injury and delirium in flu patients who were taking Tamiflu. Most of these events occurred in Japan, and the majority were in children. The possible role of the drug in contributing to these events isn't known. However, the labeling for Tamiflu now says that people with the flu, particularly children, may be at increased risk of self-injury and confusion shortly after taking Tamiflu, and so they should be closely monitored for signs of unusual behavior throughout the treatment period. Caregivers or patients should be told to contact a healthcare professional immediately if a patient taking Tamiflu shows any signs of unusual behavior.
The company's letter also alerts practitioners to the potential interaction between Tamiflu and FluMist, the intranasal flu vaccine. It notes that if they are given together, Tamiflu may inhibit the desired replication of the live virus in the intranasal vaccine. Because of this, FluMist should not be administered within two weeks before, or 48 hours after administering Tamiflu. This potential interaction is not a problem with the injectable trivalent flu vaccine.
Additional Information:
FDA MedWatch Safety Alert. Tamiflu (oseltamivir phosphate). November 13, 2006.
http://www.fda.gov/medwatch/safety/20...
The company's letter says that there have been reports of self-injury and delirium in flu patients who were taking Tamiflu. Most of these events occurred in Japan, and the majority were in children. The possible role of the drug in contributing to these events isn't known. However, the labeling for Tamiflu now says that people with the flu, particularly children, may be at increased risk of self-injury and confusion shortly after taking Tamiflu, and so they should be closely monitored for signs of unusual behavior throughout the treatment period. Caregivers or patients should be told to contact a healthcare professional immediately if a patient taking Tamiflu shows any signs of unusual behavior.
The company's letter also alerts practitioners to the potential interaction between Tamiflu and FluMist, the intranasal flu vaccine. It notes that if they are given together, Tamiflu may inhibit the desired replication of the live virus in the intranasal vaccine. Because of this, FluMist should not be administered within two weeks before, or 48 hours after administering Tamiflu. This potential interaction is not a problem with the injectable trivalent flu vaccine.
Additional Information:
FDA MedWatch Safety Alert. Tamiflu (oseltamivir phosphate). November 13, 2006.
http://www.fda.gov/medwatch/safety/20...
Efectos adversos del Tamiflu
Roche Laboratories has alerted healthcare professionals about neuropsychiatric events that have occurred in influenza patients taking Tamiflu (oseltamivir phosphate). Tamiflu is used to treat or prevent the flu in patients 1 year and older.
The company's letter says that there have been reports of self-injury and delirium in flu patients who were taking Tamiflu. Most of these events occurred in Japan, and the majority were in children. The possible role of the drug in contributing to these events isn't known. However, the labeling for Tamiflu now says that people with the flu, particularly children, may be at increased risk of self-injury and confusion shortly after taking Tamiflu, and so they should be closely monitored for signs of unusual behavior throughout the treatment period. Caregivers or patients should be told to contact a healthcare professional immediately if a patient taking Tamiflu shows any signs of unusual behavior.
The company's letter also alerts practitioners to the potential interaction between Tamiflu and FluMist, the intranasal flu vaccine. It notes that if they are given together, Tamiflu may inhibit the desired replication of the live virus in the intranasal vaccine. Because of this, FluMist should not be administered within two weeks before, or 48 hours after administering Tamiflu. This potential interaction is not a problem with the injectable trivalent flu vaccine.
Additional Information:
FDA MedWatch Safety Alert. Tamiflu (oseltamivir phosphate). November 13, 2006.
http://www.fda.gov/medwatch/safety/20...
The company's letter says that there have been reports of self-injury and delirium in flu patients who were taking Tamiflu. Most of these events occurred in Japan, and the majority were in children. The possible role of the drug in contributing to these events isn't known. However, the labeling for Tamiflu now says that people with the flu, particularly children, may be at increased risk of self-injury and confusion shortly after taking Tamiflu, and so they should be closely monitored for signs of unusual behavior throughout the treatment period. Caregivers or patients should be told to contact a healthcare professional immediately if a patient taking Tamiflu shows any signs of unusual behavior.
The company's letter also alerts practitioners to the potential interaction between Tamiflu and FluMist, the intranasal flu vaccine. It notes that if they are given together, Tamiflu may inhibit the desired replication of the live virus in the intranasal vaccine. Because of this, FluMist should not be administered within two weeks before, or 48 hours after administering Tamiflu. This potential interaction is not a problem with the injectable trivalent flu vaccine.
Additional Information:
FDA MedWatch Safety Alert. Tamiflu (oseltamivir phosphate). November 13, 2006.
http://www.fda.gov/medwatch/safety/20...
Efectos adversos del Tamiflu
Roche Laboratories has alerted healthcare professionals about neuropsychiatric events that have occurred in influenza patients taking Tamiflu (oseltamivir phosphate). Tamiflu is used to treat or prevent the flu in patients 1 year and older.
The company's letter says that there have been reports of self-injury and delirium in flu patients who were taking Tamiflu. Most of these events occurred in Japan, and the majority were in children. The possible role of the drug in contributing to these events isn't known. However, the labeling for Tamiflu now says that people with the flu, particularly children, may be at increased risk of self-injury and confusion shortly after taking Tamiflu, and so they should be closely monitored for signs of unusual behavior throughout the treatment period. Caregivers or patients should be told to contact a healthcare professional immediately if a patient taking Tamiflu shows any signs of unusual behavior.
The company's letter also alerts practitioners to the potential interaction between Tamiflu and FluMist, the intranasal flu vaccine. It notes that if they are given together, Tamiflu may inhibit the desired replication of the live virus in the intranasal vaccine. Because of this, FluMist should not be administered within two weeks before, or 48 hours after administering Tamiflu. This potential interaction is not a problem with the injectable trivalent flu vaccine.
Additional Information:
FDA MedWatch Safety Alert. Tamiflu (oseltamivir phosphate). November 13, 2006.
http://www.fda.gov/medwatch/safety/20...
The company's letter says that there have been reports of self-injury and delirium in flu patients who were taking Tamiflu. Most of these events occurred in Japan, and the majority were in children. The possible role of the drug in contributing to these events isn't known. However, the labeling for Tamiflu now says that people with the flu, particularly children, may be at increased risk of self-injury and confusion shortly after taking Tamiflu, and so they should be closely monitored for signs of unusual behavior throughout the treatment period. Caregivers or patients should be told to contact a healthcare professional immediately if a patient taking Tamiflu shows any signs of unusual behavior.
The company's letter also alerts practitioners to the potential interaction between Tamiflu and FluMist, the intranasal flu vaccine. It notes that if they are given together, Tamiflu may inhibit the desired replication of the live virus in the intranasal vaccine. Because of this, FluMist should not be administered within two weeks before, or 48 hours after administering Tamiflu. This potential interaction is not a problem with the injectable trivalent flu vaccine.
Additional Information:
FDA MedWatch Safety Alert. Tamiflu (oseltamivir phosphate). November 13, 2006.
http://www.fda.gov/medwatch/safety/20...
Suscribirse a:
Entradas (Atom)